FDA Approves ORZEYFUL for Adults With Narcolepsy Type 1
takeda.com · 2,395 words · saved by 1 readers
Takeda announces FDA approval of ORZEYFUL, a first-in-class oral orexin treatment for adults with narcolepsy type 1, pending DEA scheduling.
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process OSAKA, Japan and CAMBRIDGE, Massachusetts, August 5, 2026 – Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug…
saved by
related reading
- Ozempic For Sleepisaak.net
- Orexin - Wikipediaen.wikipedia.org
- Why Does Ozempic Cure All Diseases?astralcodexten.com
- Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher diseasesanofi.com
- Allopregnanolone - Wikipediaen.wikipedia.org
- The Ozempocalypse Is Nigh - by Scott Alexanderastralcodexten.com
- Atomoxetine: a novel treatment for child and adult ADHD - PMCpmc.ncbi.nlm.nih.gov
- List of Fictional Drugs Banned By The FDAslatestarcodex.com
- Weekly Dose of Optimism #208notboring.co
- Eliglustat - Wikipediaen.wikipedia.org
- The Psychopharmacology Of The FTX Crashastralcodexten.substack.com
- Ozempic for Sleep: Research for Safely Reducing Sleep Needsmanifund.org